5 news items
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
on >85% of medical benefit lives in health plans including Medicare Fee for Service, Medicare Advantage, and national and regional commercial plans
Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting
CHRS
8 Apr 24
therapy and potentially provide benefit to more cancer patients," said Theresa LaVallee, Ph.D., Chief Development Officer at Coherus. "CHS-1000 is our
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS
8 Apr 24
as a new immuno-therapy approach with the aim to overcome resistance to I-O therapy and potentially provide benefit to more cancer patients," said Theresa
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
(benefit
Coherus Completes Divestiture of Ophthalmology Franchise
CHRS
4 Mar 24
agents with the potential to achieve a step change in patient survival and benefit. Coherus' immuno-oncology pipeline includes multiple antibody
- Prev
- 1
- Next